E-Cadherin Expression in Endometrial Carcinoma

  • Geethika P Ullas Department of Pathology, Government Medical College Trivandrum
  • Sheela K M Department of Pathology, Government Medical College Trivandrum
Keywords: Endometrial carcinoma, E-cadherin expression, histological subtypes, Stage, Grade

Abstract

Background In this study, we wanted to determine the proportion of negative E-cadherin expression in endometrial carcinoma cases received in the Department of Pathology and evaluate the E-cadherin expression in different histological subtypes of endometrial carcinoma. Methods This was a cross-sectional study conducted over one year in the Department of Pathology, Government Medical College, Thiruvananthapuram, Kerala. 52 specimens histopathologically diagnosed as endometrial carcinoma in the Department of Pathology, were studied. Age, histological subtype, grade, stage and E-cadherin staining were recorded. Data were entered into an Excel sheet and analysed with SPSS. Result Clinicopathological features of were studied and the median age group of the patients was between         51-60 years. The majority of cases were of  endometrioid type and presented at stage IA (69.2 %). Negative  E cadherin expression was seen more commonly in Type II endometrial carcinomas (50 & 33.3 % of serous and clear cell carcinoma respectively). Among the Type I carcinoma, grade 3 tumours showed the most proportion of negative E-cadherin staining pattern (33.3 %). Conclusion: The study concluded that most of the tumours occurred in the postmenopausal age group and the majority of cases were in stage IA, most cases were of endometrioid type. E-cadherin was lost most commonly in high-grade endometrioid carcinoma and Type 2 carcinomas. Among the 3 grades of endometrioid carcinoma, grade 3 (33.3 %) had the highest proportion of negative staining and grade 1 had the highest proportion of positive staining characteristics. (57.1 %).

References

World Research Cancer Fund International. Available from: http://www.wcrf.org

Almadani N, Thompson EF, Tessier-Cloutier B, et al. An update of molecular pathology and shifting systems of classification in tumors of female genital tract. Diagn Histopathol. 2020;26(6):278-88.

Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:14.

World Health Organization. Classification of tumors of the female genital tract. 2020.

Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular‐based classification for endometrial cancers. Br J Cancer. 2015;113(2):299-310.

Trana AQ, Gehrig P. Recent advances in endometrial cancer. F1000Res. 2017;6:81.

Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol. 1994;53(2):183-9.

Saito T, Nishimura M, Yamasaki H, et al. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer. 2003;97(4):1002-9.

Bharatnur S, Kustagi P, Krishnamohan D. Endometrial carcinoma in a young woman: "30 is Not Immune". J Obstet Gynaecol India. 2011;61(6):686-8.

Yalta T, Atay L, Atalay F, et al. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res. 2009;37(1):163-8.

Balasubramaniam G, Sushama S, Rasika B, et al. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev. 2013;14(2):977-80.

Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10(16):5546-53.

Park JH, Lee BI, Song ES, et al. Hypermethylation of E-cadherin in endometrial carcinoma. J Gynecol Oncol. 2008;19(4):241-5.

Ascaño JJ, Frierson H, Moskaluk CA, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol. 2001;14(10):942-9.

Published
2024-02-04
Section
Original Article